TapImmune Inc. (OTCMKTS:TPIV) shares were up 3.04% to $0.440 on Monday as the biotech company faces positive prospects under its new leader. The company has a market cap of $53.71 million at 122.08 million shares outstanding. Shares have been trading in a 52-week range of $0.31 to $0.97 so it’s currently around the middle for now.
TapImmune recently announced the appointment of its new President and COO John Bonfiglio, who is a bioscience veteran from Tampa. He was the former President and CEO of Oragenics and has been a strategic adviser to TapImmune since 2015. His appointment is expected to help the company establish its presence in Tampa and strengthen its market in Florida.
In particular, Bonfiglio’s role will focus on running operations, making sure the company is reaching its milestones, and acquiring the right resources necessary for clinical studies. He will be working closely with chairman and CEO Glynn Wilson in bringing in the needed financing and representing the company in front of investors.
There was a need for more senior people to steer the company forward,” Bonfiglio said. “Glynn Wilson was doing everything for a while. I came on last February as a consultant, helping out, and together we made progress moving the company forward.”
TapImmune is an immuno-oncology company that focuses in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. It is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers by combining a set of licensed technologies, including peptide antigen technologies and DNA expression technologies that improve the ability of the cellular immune system to recognize and destroy diseased cells.
As it is, the company has four Phase II clinical trials underway for TPIV 200, which is a vaccine for treating breast and ovarian cancers.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
